Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human safety, tolerability, and pharmacokinetics study of IBC-Ab002 in early Alzheimer's disease
NL-OMON56092Phase 1Recruiting
- Sponsor
- ImmunoBrain Checkpoint
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of IBC-Ab002 in Alzheimer's disease (AD) (6 arms), sponsored by ImmunoBrain Checkpoint. Primary endpoint: Safety and tolerability. Started Jan 2024; status: recruiting.
02
Drugs
IBC-Ab002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON56092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56092.